NICE proposes limited febuxostat use in gout
This article was originally published in Scrip
Executive Summary
Ipsen's Adenuric (febuxostat, licensed from Teijin Pharma) is to be recommended as a treatment option in England and Wales for patients with chronic hyperuricaemia in gout only if they are intolerant of allopurinol or for whom the older drug is contraindicated. TheNational Institute for health and Clinical Excellence, which evaluates technology for the national health service, has softened its original draft guidance, which ruled out all new Adenuric use in NHS patients.